Impact of a Letter Encouraging Pneumococcal Vaccination on the 1-year Vaccination Rate in Heart Failure Patients With a Primary Care Physician
Conditions: Chronic Heart Failure Interventions: Other: Incentive letter for pneumococcal vaccination to the patient and to the GP Sponsors: University Hospital, Montpellier Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 11, 2024 Category: Research Source Type: clinical trials
A Study of the ACYW135 Meningococcal Polysaccharide Conjugate Vaccine
Conditions: Meningococcal Meningitis Interventions: Biological: ACYW135 Meningococcal Polysaccharide Conjugate Vaccine; Biological: ACYW135 Meningococcal Polysaccharide Vaccine Sponsors: Aimei Vacin BioPharm (Zhejiang) Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 29, 2024 Category: Research Source Type: clinical trials
A Study to Evaluate Tolerability, Safety and Immunogenicity of MVX01 Pneumococcal Vaccine
Conditions: Pneumococcal Vaccine Interventions: Biological: MVX01; Biological: MVX01 Placebo Sponsors: Matrivax Research and Development Corporation Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 29, 2024 Category: Research Source Type: clinical trials
Evaluation of Vaccination for Streptococcus Pneumoniae in Adults With an Episode of Invasive Pneumococcal Infection: a Retrospective Study in Two Lombardy Centers in the Pre-pandemic Phase From 2015 to 2019.
Conditions: Invasive Pneumococcal Infection Sponsors: Azienda Ospedaliera di Lecco; IRCCS Ospedale San Raffaele Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 27, 2024 Category: Research Source Type: clinical trials
Pneumococcal conjugate vaccination schedules in infants —acquisition, immunogenicity, and pneumococcal conjugate and yellow fever vaccine co-administration study: statistical analysis plan
We describe the approach to analyses and how we will account for the effect of clustering. Defining the SAP prior to the conduct of analysis will avoid bias in analyses that may arise from prior knowledge of trial findings.Trial registrationISRCTN, ISRCTN7282161328. Registered on 28 November 2019.https://www.isrctn.com/ISRCTN72821613.Protocol: MRCG SCC number 1670, LSHTM Ref 17683.Current protocol version: 6.0, 24 May 2021.Version: 1.0 (5 April 2023); SAP revisions —none. (Source: Trials)
Source: Trials - March 26, 2024 Category: Research Source Type: clinical trials
Merck Announces Positive Data on V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Demonstrated Immune Responses in Adults
RAHWAY, N.J.--(BUSINESS WIRE) March 19, 2024 -- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive data from multiple Phase 3 studies evaluating V116, the company’s investigational,... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - March 19, 2024 Category: Pharmaceuticals Source Type: clinical trials
Clinical Study on Lot-to-lot Consistency and Immune Persistence of Three Commercial Batches of PPSV23
Conditions: Healthy Volunteers Interventions: Biological: 23 Valent Pneumococcal Polysaccharide Vaccine (lot 1); Biological: 23 Valent Pneumococcal Polysaccharide Vaccine (lot 2); Biological: 23 Valent Pneumococcal Polysaccharide Vaccine (lot 3) Sponsors: Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 18, 2024 Category: Research Source Type: clinical trials
Phase I Clinical Trial of Recombinant Meningococcal Group B Vaccine (E. Coli) in a Population Aged 3 Months-50 Years Old
Conditions: Healthy Volunteers Interventions: Biological: Recombinant Meningococcal Group B Vaccine (E. Coli) (low-dose); Biological: Recombinant Meningococcal Group B Vaccine (E. Coli) (hign-dose); Biological: Placebo control Sponsors: Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 18, 2024 Category: Research Source Type: clinical trials
Immunogenicity and Safety of Group A and C Meningococcal Polysaccharide Conjugate Vaccine in Volunteers Aged 3-5 Months
Conditions: Healthy Population Interventions: Biological: Group A and C Meningococcal Polysaccharide Conjugate Vaccine (producted by Zhifei Lvzhu); Biological: Group A and C Meningococcal Polysaccharide Conjugate Vaccine (producted by Walvax); Biological: Group A and C Meningococcal Polysaccharide Conjugate Vaccine (producted by Olymvax) Sponsors: Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 18, 2024 Category: Research Source Type: clinical trials
Immunogenicity and Safety of MCV4 in Volunteers Aged 6 Months-5 Years
Conditions: Healthy Population Interventions: Biological: Group ACYW135 Meningococcal Polysaccharide Conjugate Vaccine; Biological: Group A and C Meningococcal Polysaccharide Vaccine; Biological: Group ACYW135 Meningococcal Polysaccharide Vaccine Sponsors: Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 18, 2024 Category: Research Source Type: clinical trials
Study on Immunogenicity and Safety of a Meningococcal ACYW Conjugate Vaccine in Healthy Infants and Toddlers
Conditions: Healthy Volunteers (Meningococcal Immunisation) Interventions: Biological: MenACYW conjugate vaccine; Biological: MenACYW conjugate vaccine Sponsors: Sanofi Pasteur, a Sanofi Company Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 29, 2024 Category: Research Source Type: clinical trials
Evaluation of PCV15 Vaccination Among PPSV23-experienced, Immunocompromised Elderly Veterans
Conditions: Pneumococcal Vaccines; Immunosuppression Interventions: Drug: 15-valent pneumococcal conjugate vaccine; Drug: 23-valent pneumococcal polysaccharide vaccine Sponsors: VA Sierra Nevada Health Care System; Merck Sharp& Dohme LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 22, 2024 Category: Research Source Type: clinical trials
Education to Improve Pneumococcal Vaccine Uptake Among Older Adults
Conditions: Pneumococcal Vaccine Uptake; Vaccination Willingness; Pneumococcal Vaccine Knowledge; Pneumococcal Vaccine Attitude Interventions: Other: Web-based educational video on pneumococcal vaccination; Other: Reminder email to be vaccinated Sponsors: University of Ottawa Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 31, 2024 Category: Research Source Type: clinical trials
Study on a MenACYW Conjugate Vaccine Administered as a Single Dose in Participants Aged 12 Months and Older in Vietnam
Conditions: Meningococcal Infection (Healthy Volunteers) Interventions: Biological: Meningococcal Polysaccharide (Serogroups A, C, W, and Y) Tetanus Toxoid Conjugate Vaccine Sponsors: Sanofi Pasteur, a Sanofi Company Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 29, 2024 Category: Research Source Type: clinical trials
A Clinical Trial of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) in 18-59 Year Olds
Conditions: Meningococcal Meningitis Interventions: Biological: MCV4; Biological: MPSV4 Sponsors: CanSino Biologics Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 26, 2024 Category: Research Source Type: clinical trials
